Research programme: immunomodulating bacteria-based therapeutics - GT Biologics

Drug Profile

Research programme: immunomodulating bacteria-based therapeutics - GT Biologics

Alternative Names: Live biotherapeutics - GT Biologics; Rosburix™

Latest Information Update: 17 Oct 2013

Price : $50

At a glance

  • Originator GT Biologics
  • Class Bacteria
  • Mechanism of Action Bacteria replacements; Immunomodulators; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Inflammatory bowel diseases

Highest Development Phases

  • Preclinical Crohn's disease; Inflammatory bowel diseases

Most Recent Events

  • 17 Oct 2013 Preclinical trials in Inflammatory bowel disease in United Kingdom (PO)
  • 17 Oct 2013 Inflammatory bowel disease therapeutics are available for licensing as of 17 Oct 2013. http://www.gt-biologics.com
  • 07 Oct 2013 Preclinical trials in Crohn's disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top